These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 32739231)

  • 1. Specificities of small cell neuroendocrine prostate cancer: Adverse prognostic value of TTF1 expression.
    Cancel M; Castellier C; Debiais-Delpech C; Charles T; Rozet F; Rioux-Leclercq N; Mathieu R; Beltjens F; Cormier L; Bruyère F; Fromont G
    Urol Oncol; 2021 Jan; 39(1):74.e17-74.e23. PubMed ID: 32739231
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Neuroendocrine prostate cancer (NEPCa) increased the neighboring PCa chemoresistance via altering the PTHrP/p38/Hsp27/androgen receptor (AR)/p21 signals.
    Cui Y; Sun Y; Hu S; Luo J; Li L; Li X; Yeh S; Jin J; Chang C
    Oncogene; 2016 Nov; 35(47):6065-6076. PubMed ID: 27375022
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunohistochemical study of the neural development transcription factors (TTF1, ASCL1 and BRN2) in neuroendocrine prostate tumours.
    Rodríguez-Zarco E; Vallejo-Benítez A; Umbría-Jiménez S; Pereira-Gallardo S; Pabón-Carrasco S; Azueta A; González-Cámpora R; Espinal PS; García-Escudero A
    Actas Urol Esp; 2017 Oct; 41(8):529-534. PubMed ID: 28285791
    [TBL] [Abstract][Full Text] [Related]  

  • 4. An immunohistochemical study of cervical neuroendocrine carcinomas: Neoplasms that are commonly TTF1 positive and which may express CK20 and P63.
    McCluggage WG; Kennedy K; Busam KJ
    Am J Surg Pathol; 2010 Apr; 34(4):525-32. PubMed ID: 20182342
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Neuroendocrine prostate cancer has distinctive, non-prostatic HOX code that is represented by the loss of HOXB13 expression.
    Cheng S; Yang S; Shi Y; Shi R; Yeh Y; Yu X
    Sci Rep; 2021 Feb; 11(1):2778. PubMed ID: 33531604
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prostate carcinoma with amphicrine features: further refining the spectrum of neuroendocrine differentiation in tumours of primary prostatic origin?
    Prendeville S; Al-Bozom I; Compérat E; Sweet J; Evans AJ; Ben-Gashir M; Mete O; van der Kwast TH; Downes MR
    Histopathology; 2017 Dec; 71(6):926-933. PubMed ID: 28756619
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Programmed Death Ligand 1 (PD-L1) Status and Tumor-Infiltrating Lymphocytes in Hot Spots of Primary and Liver Metastases in Prostate Cancer With Neuroendocrine Differentiation.
    von Hardenberg J; Hartmann S; Nitschke K; Worst TS; Ting S; Reis H; Nuhn P; Weis CA; Erben P
    Clin Genitourin Cancer; 2019 Apr; 17(2):145-153.e5. PubMed ID: 30709785
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic significance of neuroendocrine differentiation, proliferation activity and androgen receptor expression in prostate cancer.
    Segawa N; Mori I; Utsunomiya H; Nakamura M; Nakamura Y; Shan L; Kakudo K; Katsuoka Y
    Pathol Int; 2001 Jun; 51(6):452-9. PubMed ID: 11422807
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Human ASH1 expression in prostate cancer with neuroendocrine differentiation.
    Rapa I; Ceppi P; Bollito E; Rosas R; Cappia S; Bacillo E; Porpiglia F; Berruti A; Papotti M; Volante M
    Mod Pathol; 2008 Jun; 21(6):700-7. PubMed ID: 18311112
    [TBL] [Abstract][Full Text] [Related]  

  • 10. De novo neuroendocrine transdifferentiation in primary prostate cancer-a phenotype associated with advanced clinico-pathologic features and aggressive outcome.
    Abdulfatah E; Reichert ZR; Davenport MS; Chinnaiyan AM; Dadhania V; Wang X; Mannan R; Kunju LP; Hollenbeck BK; Montgomery JS; Kaffenberger SD; Morgan TM; Alva AS; Palapattu GS; Vaishampayan UN; Alumkal JJ; Spratt DE; Udager AM; Mehra R
    Med Oncol; 2021 Feb; 38(3):26. PubMed ID: 33586037
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Expression of neuroendocrine markers in non-neuroendocrine endometrial carcinomas.
    Moritz AW; Schlumbrecht MP; Nadji M; Pinto A
    Pathology; 2019 Jun; 51(4):369-374. PubMed ID: 31040050
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tissue microarray analysis of neuroendocrine differentiation and its prognostic significance in breast cancer.
    Makretsov N; Gilks CB; Coldman AJ; Hayes M; Huntsman D
    Hum Pathol; 2003 Oct; 34(10):1001-8. PubMed ID: 14608533
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Large cell neuroendocrine carcinoma of prostate: a clinicopathologic summary of 7 cases of a rare manifestation of advanced prostate cancer.
    Evans AJ; Humphrey PA; Belani J; van der Kwast TH; Srigley JR
    Am J Surg Pathol; 2006 Jun; 30(6):684-93. PubMed ID: 16723845
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Expression of Insulinoma-Associated Protein 1 (INSM1) and Orthopedia Homeobox (OTP) in Tumors with Neuroendocrine Differentiation at Rare Sites.
    Roy M; Buehler DG; Zhang R; Schwalbe ML; Baus RM; Salamat MS; Lloyd RV; Rosenbaum JN
    Endocr Pathol; 2019 Mar; 30(1):35-42. PubMed ID: 30523500
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Neuroendocrine differentiation in prostate carcinoma: focusing on its pathophysiologic mechanisms and pathological features.
    Alberti C
    G Chir; 2010; 31(11-12):568-74. PubMed ID: 21232206
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The expression of TTF1, CDX2 and ISL1 in 74 poorly differentiated neuroendocrine carcinomas.
    Lee H; Fu Z; Koo BH; Sheehan CE; Young GQ; Lin J; Patil DT; Yang Z
    Ann Diagn Pathol; 2018 Dec; 37():30-34. PubMed ID: 30236546
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical, pathologic, and molecular features of amphicrine prostate cancer.
    Graham LS; Haffner MC; Sayar E; Gawne A; Schweizer MT; Pritchard CC; Coleman I; Nelson PS; Yu EY
    Prostate; 2023 May; 83(7):641-648. PubMed ID: 36779357
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Clinicopathologic features of primary renal neuroendocrine carcinoma].
    Wang XH; Lu X; He B; Jiang YX; Yu WJ; Wang H; Zhang W; Li YJ
    Zhonghua Bing Li Xue Za Zhi; 2018 Nov; 47(11):851-856. PubMed ID: 30423609
    [No Abstract]   [Full Text] [Related]  

  • 19. Prognostic implications of neuroendocrine differentiation and hormone production in patients with Stage I nonsmall cell lung carcinoma.
    Pelosi G; Pasini F; Sonzogni A; Maffini F; Maisonneuve P; Iannucci A; Terzi A; De Manzoni G; Bresaola E; Viale G
    Cancer; 2003 May; 97(10):2487-97. PubMed ID: 12733148
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Different profiles of neuroendocrine cell differentiation evolve in the PC-310 human prostate cancer model during long-term androgen deprivation.
    Jongsma J; Oomen MH; Noordzij MA; Van Weerden WM; Martens GJ; van der Kwast TH; Schröder FH; van Steenbrugge GJ
    Prostate; 2002 Mar; 50(4):203-15. PubMed ID: 11870798
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.